Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives

被引:24
|
作者
Flegg, Jennifer A. [1 ,2 ]
Guerin, Philippe J. [1 ,2 ]
Nosten, Francois [2 ,3 ,4 ]
Ashley, Elizabeth A. [2 ,3 ]
Phyo, Aung Pyae [3 ,4 ]
Dondorp, Arjen M. [2 ,3 ]
Fairhurst, Rick M. [5 ]
Socheat, Duong [6 ]
Borrmann, Steffen [7 ]
Bjorkman, Anders [8 ]
Martensson, Andreas [8 ,9 ]
Mayxay, Mayfong [10 ]
Newton, Paul N. [2 ,10 ]
Bethell, Delia [11 ]
Se, Youry [12 ]
Noedl, Harald [13 ]
Diakite, Mahamadou [14 ]
Djimde, Abdoulaye A. [14 ]
Hien, Tran T. [2 ,15 ]
White, Nicholas J. [2 ,3 ]
Stepniewska, Kasia [1 ,2 ]
机构
[1] Univ Oxford, WorldWide Antimalarial Resistance Network WWARN, Oxford, England
[2] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford, England
[3] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand
[4] Mahidol Univ, Fac Trop Med, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Mae Sot, Thailand
[5] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA
[6] Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia
[7] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Kilifi, Kenya
[8] Karolinska Inst, Dept Med Solna, Infect Dis Unit, Stockholm, Sweden
[9] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden
[10] Mahosot Hosp, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit L, Microbiol Lab, Viangchan, Laos
[11] AFRIMS, Dept Immunol & Med, Bangkok, Thailand
[12] AFRIMS, Phnom Penh, Cambodia
[13] Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, Vienna, Austria
[14] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali
[15] OUCRU, Ho Chi Minh City, Vietnam
来源
MALARIA JOURNAL | 2013年 / 12卷
关键词
Plasmodium falciparum; Malaria; Artemisinin resistance; Parasite clearance; Simulation; PARASITE CLEARANCE; MALARIA; ARTESUNATE; RESISTANCE; CAMBODIA;
D O I
10.1186/1475-2875-12-411
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The emergence of Plasmodium falciparum resistance to artemisinins in Southeast Asia threatens the control of malaria worldwide. The pharmacodynamic hallmark of artemisinin derivatives is rapid parasite clearance (a short parasite half-life), therefore, the in vivo phenotype of slow clearance defines the reduced susceptibility to the drug. Measurement of parasite counts every six hours during the first three days after treatment have been recommended to measure the parasite clearance half-life, but it remains unclear whether simpler sampling intervals and frequencies might also be sufficient to reliably estimate this parameter. Methods: A total of 2,746 parasite density-time profiles were selected from 13 clinical trials in Thailand, Cambodia, Mali, Vietnam, and Kenya. In these studies, parasite densities were measured every six hours until negative after treatment with an artemisinin derivative (alone or in combination with a partner drug). The WWARN Parasite Clearance Estimator (PCE) tool was used to estimate "reference" half-lives from these six-hourly measurements. The effect of four alternative sampling schedules on half-life estimation was investigated, and compared to the reference half-life (time zero, 6, 12, 24 (A1); zero, 6, 18, 24 (A2); zero, 12, 18, 24 (A3) or zero, 12, 24 (A4) hours and then every 12 hours). Statistical bootstrap methods were used to estimate the sampling distribution of half-lives for parasite populations with different geometric mean half-lives. A simulation study was performed to investigate a suite of 16 potential alternative schedules and half-life estimates generated by each of the schedules were compared to the "true" half-life. The candidate schedules in the simulation study included (among others) six-hourly sampling, schedule A1, schedule A4, and a convenience sampling schedule at six, seven, 24, 25, 48 and 49 hours. Results: The median (range) parasite half-life for all clinical studies combined was 3.1 (0.7-12.9) hours. Schedule A1 consistently performed the best, and schedule A4 the worst, both for the individual patient estimates and for the populations generated with the bootstrapping algorithm. In both cases, the differences between the reference and alternative schedules decreased as half-life increased. In the simulation study, 24-hourly sampling performed the worst, and six-hourly sampling the best. The simulation study confirmed that more dense parasite sampling schedules are required to accurately estimate half-life for profiles with short half-life (<= three hours) and/or low initial parasite density (<= 10,000 per mu L). Among schedules in the simulation study with six or fewer measurements in the first 48 hours, a schedule with measurements at times (time windows) of 0 (0-2), 6 (4-8), 12 (10-14), 24 (22-26), 36 (34-36) and 48 (46-50) hours, or at times 6, 7 (two samples in time window 5-8), 24, 25 (two samples during time 23-26), and 48, 49 (two samples during time 47-50) hours, until negative most accurately estimated the "true" half-life. For a given schedule, continuing sampling after two days had little effect on the estimation of half-life, provided that adequate sampling was performed in the first two days and the half-life was less than three hours. If the measured parasitaemia at two days exceeded 1,000 per mu L, continued sampling for at least once a day was needed for accurate half-life estimates. Conclusions: This study has revealed important insights on sampling schedules for accurate and reliable estimation of Plasmodium falciparum half-life following treatment with an artemisinin derivative (alone or in combination with a partner drug). Accurate measurement of short half-lives (rapid clearance) requires more dense sampling schedules (with more than twice daily sampling). A more intensive sampling schedule is, therefore, recommended in locations where P. falciparum susceptibility to artemisinins is not known and the necessary resources are available. Counting parasite density at six hours is important, and less frequent sampling is satisfactory for estimating long parasite half-lives in areas where artemisinin resistance is present.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Plasmodium falciparum Clearance Is Pitting-Dependent With Artemisinin-Based Drugs but Pitting-Independent With Atovaquone-Proguanil or Mefloquine
    Wojnarski, Mariusz
    Mouri, Oussama
    Chambrion, Charlotte
    Roussel, Camille
    Chartre, Nathalie
    Smith, Bryan
    Smith, Philip
    Thellier, Marc
    Buffet, Pierre
    Ndour, Papa Alioune
    JOURNAL OF INFECTIOUS DISEASES, 2019, 220 (03) : 535 - 539
  • [32] Pharmacokinetic Profile of Artemisinin Derivatives and Companion Drugs Used in Artemisinin-Based Combination Therapies for the Treatment of Plasmodium falciparum Malaria in Children
    Shane A. Pawluk
    Kyle J. Wilby
    Mary H. H. Ensom
    Clinical Pharmacokinetics, 2013, 52 : 153 - 167
  • [33] Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?
    Tsombeng, Francis Foguim
    Gendrot, Mathieu
    Robert, Marie Gladys
    Madamet, Marylin
    Pradines, Bruno
    MALARIA JOURNAL, 2019, 18 (01)
  • [34] Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance
    Obaro S Michael
    Grace O Gbotosho
    Onikepe A Folarin
    Titilope Okuboyejo
    Akintunde Sowunmi
    Ayoade MJ Oduola
    Christian T Happi
    Malaria Journal, 9
  • [35] Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia
    Watts, Rebecca E.
    Odedra, Anand
    Marquart, Louise
    Webb, Lachlan
    Abd-Rahman, Azrin N.
    Cascales, Laura
    Chalon, Stephan
    Rebelo, Maria
    Pava, Zuleima
    Collins, Katharine A.
    Pasay, Cielo
    Chen, Nanhua
    Peatey, Christopher L.
    Mohrle, Jorg J.
    McCarthy, James S.
    PLOS MEDICINE, 2020, 17 (08)
  • [36] Monitoring artemisinin resistance in Plasmodium falciparum: comparison of parasite clearance time by microscopy and real-time PCR and evaluation of mutations in Pfatpase6 gene in Odisha state of India
    Gupta, Ruchi
    Mishra, Neelima
    Kumar, Ashwani
    Rana, Roma
    Srivastava, Bina
    Tyagi, P. K.
    Anvikar, Anupkumar R.
    Valecha, Neena
    PARASITOLOGY RESEARCH, 2015, 114 (09) : 3487 - 3496
  • [37] Global distribution of polymorphisms associated with delayed Plasmodium falciparum parasite clearance following artemisinin treatment: Genotyping of archive blood samples
    Murai, Kenji
    Culleton, Richard
    Hisaoka, Teruhiko
    Endo, Hiroyoshi
    Mita, Toshihiro
    PARASITOLOGY INTERNATIONAL, 2015, 64 (03) : 267 - 273
  • [38] Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
    Kris M Jamsen
    Stephen B Duffull
    Joel Tarning
    Niklas Lindegardh
    Nicholas J White
    Julie A Simpson
    Malaria Journal, 10
  • [39] Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015
    Ljolje, Dragan
    Dimbu, Pedro Rafael
    Kelley, Julia
    Goldman, Ira
    Nace, Douglas
    Macaia, Aleixo
    Halsey, Eric S.
    Ringwald, Pascal
    Fortes, Filomeno
    Udhayakumar, Venkatachalam
    Talundzic, Eldin
    Lucchi, Naomi W.
    Plucinski, Mateusz M.
    MALARIA JOURNAL, 2018, 17
  • [40] Artemisinin-based combination therapy successfully treated two hyperparasitaemic Plasmodium falciparum cases
    Mukhi, Benudhar
    Gupta, Himanshu
    Punnath, Kishore
    Anvikar, Anupkumar R.
    Srivastava, Bina
    Ghosh, Susanta Kumar
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2023, 17 (05): : 725 - 731